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SUPPLEMENTAL INFORMATION 
 
SUPPLEMENTAL METHODS 
 
IGAP Cohort 
International Genomics of Alzheimer's Project (IGAP)1 is a large two-stage study based 
upon genome-wide association studies (GWAS) on individuals of European ancestry. 
In stage 1, IGAP used genotyped and imputed data on 7,055,881 single nucleotide 
polymorphisms (SNPs) to meta-analyse four previously-published GWAS datasets 
consisting of 17,008 Alzheimer's disease cases and 37,154 controls (The European 
Alzheimer's disease Initiative – EADI the Alzheimer Disease Genetics Consortium – 
ADGC The Cohorts for Heart and Aging Research in Genomic Epidemiology 
consortium – CHARGE The Genetic and Environmental Risk in AD consortium – 
GERAD). In stage 2, 11,632 SNPs were genotyped and tested for association in an 
independent set of 8,572 Alzheimer's disease cases and 11,312 controls. Finally, a 
meta-analysis was performed combining results from stages 1 & 2. 
 
The institutional review boards of all participating institutions approved the 
procedures for IGAP substudies. Written informed consent was obtained from all 
participants or surrogates. 
ADNI cohort  
Data used in the preparation of this article were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched 
in 2003 as a public-private partnership, led by Principal Investigator Michael W. 
Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic 
resonance imaging (MRI), positron emission tomography (PET), other biological 
markers, and clinical and neuropsychological assessment can be combined to measure 
the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease 
(AD). 
Each participant was formally evaluated using eligibility criteria that are 
described in detail elsewhere 
(http://www.adni-info.org/index.php?option=com_content&task=view&id=9&Itemid
=43). The institutional review boards of all participating institutions approved the 
procedures for this study. Written informed consent was obtained from all participants 
or surrogates. Experienced clinicians conducted independent semi-structured 
interviews with the participant and a knowledgeable collateral source that included a 
health history, neurological examination, and a comprehensive neuropsychological 
battery. We selected participants from the ADNI database if they were clinically 
diagnosed at baseline as cognitively normal, amnestic mild cognitive impairment 
(MCI) as defined using the revised MCI criteria or probable AD. 
 
Deriving Polygenic Hazard Scores 
Selecting set of previously implicated SNPs 
We utilized previously published summary statistics (p-values and odds ratios) for AD 
associated SNPs from the IGAP consortium.1 Because the effect size estimates from 
the GWAS represent odds ratios that do not contain the time-to-event information, we 
did not use the estimated effect size from IGAP consortium. Instead, we only used the 
SNP list as a triage to filtering out most of unrelated SNPs. We set the significance 
threshold to p-value < 10-5 as the criteria for association with AD status. Among all 
IGAP stage 1 SNPs, we found 1854 SNPs with p-values < 10-5. From this list, we then 
used a forward stepwise regression to select SNPs for the final Cox proportional model. 
The final SNP selection process was conducted using the ADGC phase 1 cohort, 
excluding samples from NACC and ADNI. We further imputed with the missing 
genotypes in cohorts as the population mean, treating them as missing at random. 
 
Forward stepwise Cox regression with conditional partial likelihood 
To build the predictive model for AD age of onset, we adopted an approach that 
reduced the effect of linkage disequilibrium and further examined the effect of genetic 
loci on survival time. In each step, the algorithm includes one SNP that most 
minimized the Martingale regression residuals, and halts if no SNPs can further 
minimize the residuals. The Cox regressions were fitted with conditional partial 
likelihood: 
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Here, d represents each distinct time-event and R is the sampled risk set in the event 
time tj. Time-ties were solved with Efron’s method. Throughout the fitting process, we 
controlled for the effects of gender, APOE variants, and the top five genetic principal 
components. The selection procedures were conducted on the ADGC phase 1 cohort. 
In the final model, we identified 31 SNPs, in addition to the two APOE variants, that 
were associated with AD age of onset.  
 
Calculating individualized absolute hazards 
Instead of estimating the baseline hazard from the ADGC cohort, which is biased due 
to over-sampling of cases, we used the previously reported annualized incidence rates 
by age2 and then converted this into disease onset rates, R, as: 
𝑅(𝑎𝑔𝑒) = 1 − 𝑆(𝑎𝑔𝑒) ≈ 1 − exp (− ∑ 𝐼𝑘
𝑎𝑔𝑒
𝑘=60
) 
S is the survival function, k is the age strata from 60 years old to age in years and the 
Ik is the annualized incidence rates given the age strata k. Combining this baseline 
hazard with the hazard ratios estimates from the previous section, we then derived the 
corrected survival function that predicts an individual’s risk of developing AD, given 
their polygenic profile and age. The incidence rates were also predicted given the 
individuals’ genetic background and their population baseline, as the annualized rate 
is the instantaneous hazard function converted from the corrected survival function: 
𝐴𝑛𝑛𝑢𝑎𝑙𝑖𝑧𝑒𝑑 𝐼𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑟𝑎𝑡𝑒𝑠 =  𝜆0exp (𝑋𝛽) 
For λ0 is the instantaneous hazard function from previous reports2, the 𝛽 is the Cox 
coefficients estimated in previous steps, assuming the genotypes X were centered on 
population mean. We used allele frequencies from 503 European descendants from 
the 1000 Genome Project to ensure proper centering and correct for sampling bias. 
We estimated the uncertainty of predicted incidence rates solely on the model 
estimates from ADGC cohorts because the previous published US population baseline 
annualized incidence rate estimates2 did not provide confidence intervals. Assuming 
𝑋?̂?is asymptotically normal, centering on 0, the variance of predicted incidence 
proportions were derived using the delta method.  
  
Assessing Prediction Accuracy in Independent Cohorts 
We used one independent case-control sample, ADGC phase 2, and one longitudinal 
cohort, NACC, to evaluate the performance of PHS. First we used the PHS to 
generate the predicted age at onset in ADGC phase 2, and compared that to the 
corresponding empirical age at onset observed in ADGC phase 2. The observations 
were binned into 100 percentile bins to ensure the reliability of the empirical age at 
onset. Pearson correlations were calculated for the linear relationships between 
predicted and empirical age at onset in the ADGC phase 2. To take the censoring 
process into consideration, we also examined whether the PHS provides information 
for differentiating risk strata in the survival context. We used the likelihood ratio test 
to determine whether the PHS predicted the proportional risk in ADGC phase 2, while 
visualizing the stratification using Kaplan-Meier curves given strata in quartiles.  
We then used the NACC longitudinal cohort to determine whether the PHS 
predicted progression from normal aging to AD. We focused on cognitively normal 
individuals who were followed for at least two years. Given the risk strata defined by 
PHS, we assessed whether the rate of AD onset is proportional to the increment of 
PHS. We used the Cochrane-Armitage test for trends to evaluate the association 
between PHS and empirical progression rate of AD.  
 
MR Image Processing 
 All ADNI MRI scans were acquired at multiple sites using either a GE, Siemens, 
or Philips 1.5T system. Parameter values vary depending on scanning site and can be 
found http://adni.loni.usc.edu/. Multiple high-resolution T1- weighted volumetric 
MRI scans were collected for each subject and the raw DICOM images were 
downloaded from the public ADNI site 
(http://adni.loni.usc.edu/data-samples/access-data/). All MRI scans were analyzed 
using a modified version of the FreeSurfer software package 
(http://surfer.nmr.mgh.harvard.edu). These analysis procedures have been applied, 
validated, and described in detail in a number of publications. 3 In brief, the MRI 
scans were reviewed for quality, automatically corrected for spatial distortion due to 
gradient nonlinearity 4, registered and averaged to improve the signal to noise ratio. 
The cortical surface was automatically reconstructed 5,6 and gray matter thickness 
measurements were obtained at each point across the cortical mantle. 7  
In this study, we primarily focused on the entorhinal cortex and hippocampus 
because AD-specific pathology is evident in this region in the earliest stages of the 
disease process. 8-10 The entorhinal cortex was delineated using an automated, 
surface-based parcellation atlas. 11 The hippocampus was identified using an 
automated, subcortical, segmentation atlas. 12 For the analysis of the longitudinal 
volume change, gray matter thickness change was examined using Quarc (quantitative 
anatomical regional change), a recently developed method from our laboratory. 13-14 
Briefly, each participant's follow-up image was affine-aligned to the baseline scan and 
locally intensity-normalized. Using nonlinear registration, a deformation field was 
then calculated to locally register the images with high fidelity for both large- and 
small-scale structures, including those with low boundary contrast. From the 
deformation field, a volume-change field (atrophy) can directly be calculated. Using 
the baseline subcortical and cortical labels, the volume-change field can be sampled at 
points across the cortical surface or averaged over subcortical regions to give the 
percent volume change for those regions of interest.  
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SUPPLEMENTAL FIGURE 
Supplemental Figure 1. Frequency distribution of APOE ε 2/3/4 alleles as a function 
of PHS and years to AD onset (Age). As illustrated, the risk of developing AD 
corresponds to increasing PHS. Positive age values represent years free of AD and 
negative age values represent age to AD onset. 
 
Supplemental Figure 2. (A) Survival functions stratified by polygenic hazard scores 
(PHS) and APOE 4 status. The survival functions were predicted based on the 
population baseline and the estimated hazard ratios from the Cox regression. The 
survival functions are stratified according to the PHS percentiles and APOE ε4 carrier 
status, where APOE ε4+ represents ‘carriers’ and APOE ε4- represents ‘non-carriers’. 
(B) Predicted AD age of onset distribution. Based on the population baseline 
corrected survival function, the distribution of AD age of onset is illustrated. 
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